GKV Capital Management Co. Inc. Takes $267,000 Position in Gilead Sciences, Inc. $GILD

Key Points

• GKV Capital Management Co. Inc. has acquired a new stake in Gilead Sciences, purchasing 2,387 shares valued at approximately $267,000.
• Gilead Sciences has received multiple positive rating upgrades from analysts, with targets ranging from $96.00 to $133.00, indicating a potential for growth in stock performance.
• The company reported $2.01 earnings per share for the last quarter, exceeding analyst estimates and showing a revenue increase of 1.4% compared to the previous year.

GKV Capital Management Co. Inc. bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,387 shares of the biopharmaceutical company's stock, valued at approximately $267,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Smallwood Wealth Investment Management LLC purchased a new position in Gilead Sciences during the first quarter worth about $25,000. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Colonial Trust Advisors lifted its holdings in shares of Gilead Sciences by 304.3% in the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock valued at $32,000 after buying an additional 213 shares during the period. Core Alternative Capital boosted its stake in shares of Gilead Sciences by 370.8% in the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after buying an additional 241 shares in the last quarter. Finally, IMA Advisory Services Inc. purchased a new position in Gilead Sciences in the first quarter worth $39,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have commented on GILD shares. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price objective on the stock in a report on Tuesday, August 19th. UBS Group boosted their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Finally, Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, August 19th. Three research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $115.39.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total transaction of $548,700.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $978,880.80. The trade was a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $113.63, for a total value of $1,136,300.00. Following the completion of the transaction, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. The trade was a 1.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,371,330 in the last quarter. Company insiders own 0.27% of the company's stock.

Gilead Sciences Stock Up 0.4%

Shares of NASDAQ:GILD traded up $0.41 during mid-day trading on Monday, hitting $112.97. 4,629,720 shares of the company traded hands, compared to its average volume of 6,308,101. The firm's 50 day simple moving average is $113.01 and its 200 day simple moving average is $109.66. The firm has a market cap of $140.17 billion, a P/E ratio of 22.50, a PEG ratio of 0.70 and a beta of 0.36. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. Gilead Sciences, Inc. has a 52-week low of $77.74 and a 52-week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business's quarterly revenue was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences's dividend payout ratio is currently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.